Intermediate-Risk Prostate Cancer |
Image Credit: © Sebastian Kaulitzki – stock.adobe.com
At 15 years of follow-up, external beam radiation therapy (EBRT) with or without short-term neoadjuvant androgen deprivation therapy (STAD) led to improved prostate cancer–specific survival among patients with intermediate-risk prostate cancer (IRPC), according to data presented at the 2025 Genitourinary Cancers Symposium.1
Data from the trial revealed that at a median follow-up of 12.0 years and a maximum of 19.8 years, the 15-year prostate cancer–specific survival (PCSS) rate was 91% for patients with IRPC undergoing STAD plus EBRT and those receiving EBRT alone (P = .67). Additionally, the 15-year overall survival (OS) rate was 53% for those undergoing STAD plus EBRT and 51%…